Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoradiotherapy + chidamide + PD-1 for advanced solid tumors (breast cancer and soft tissue sarcoma)
ChiCTR2300068737Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab and tucidinostat in breast cancer and soft tissue sarcoma (STS) (2 cohorts), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: progression-free survival. Started Jul 2022; status: recruiting.
02
Drugs
sintilimabtucidinostat
03
Conditions
breast cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300068737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068737.